CYD-2-11

CAS No. 1425944-22-4

CYD-2-11( CYD-2-11 | CYD 2 11 | CYD211 )

Catalog No. M11797 CAS No. 1425944-22-4

CYD-2-11 is a novel potent, selective Bax agonist that targets the structural pocket proximal to S184 in the C-terminal region of Bax (Ki=34.1 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CYD-2-11
  • Note
    Research use only, not for human use.
  • Brief Description
    CYD-2-11 is a novel potent, selective Bax agonist that targets the structural pocket proximal to S184 in the C-terminal region of Bax (Ki=34.1 nM).
  • Description
    CYD-2-11 is a novel potent, selective Bax agonist that targets the structural pocket proximal to S184 in the C-terminal region of Bax (Ki=34.1 nM); shows no affinity for other Bcl-2 family members; directly activates Bax proapoptotic activity by inducing a conformational change enabling formation of Bax homooligomers in mitochondrial membranes; suppresses malignant growth without evident significant toxicity to normal tissues in mutant KRAS-driven lung cancer models; displays strong synergistic activity and overcomes rapalog resistance combined with RAD001.
  • In Vitro
    CYD-2-11 (0-100 μM; 48 h) shows anti-proliferation effects to breast cancer cells.CYD-2-11 (5 μM; 48 h) selectively binds to Bax protein and induces apoptosis in NSCLC and SCLC cell lines. Cell Proliferation Assay Cell Line:T47D, MCF-7, MDA-MB-231, MDA-MB-468 and MCF-10A cell lines Concentration:0.01, 0.1, 1, 5, 10 and 100 μM Incubation Time:48 hours Result:Inhibited cell proliferation of T47D, MCF-7, MDA-MB-231, MDA-MB-468 and MCF-10A cells with IC50 values of 4.37, 9.47, 3.81, 3.22 and 8.73 μM, respectively.Apoptosis Analysis Cell Line:SCLC and NSCLC cell lines Concentration:5 μM Incubation Time:48 hours Result:Induced cell apoptosis in both SCLC and NSCLC cells with a higher effect than SMBA1.
  • In Vivo
    CYD-2-11 (20 mg/kg; i.p.; once daily for 7 days) inhibits tumor growth.CYD-2-11 (40 mg/kg; i.p.; once daily for 14 days) represses lung cancer growth and overcomes rapalog resistance with the combination of RAD001 (1 mg/kg) in murine lung cancer models. Animal Model:Female nude mice with MDA-MB-231 tumor xenografts Dosage:20 mg/kg Administration:Intraperitoneal injection; 20 mg/kg; once daily for 7 days Result:Exhibited a 57% inhibition rate of MDA-MB-231 tumor growth in vivo.
  • Synonyms
    CYD-2-11 | CYD 2 11 | CYD211
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Bcl-2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1425944-22-4
  • Formula Weight
    358.397
  • Molecular Formula
    C22H18N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    NCCOC1=CC=CC=C1/C=C2C3=C(C4=C/2C=CC=C4)C=CC([N+]([O-])=O)=C3
  • Chemical Name
    (E)-2-(2-((2-nitro-9H-fluoren-9-ylidene)methyl)phenoxy)ethan-1-amine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Li R, et al. Cancer Res. 2017 Jun 1;77(11):3001-3012.
molnova catalog
related products
  • SW063058

    SW063058 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.

  • AZD 5991

    AZD 5991 (AZD5991) is a potent and selective macrocyclic inhibitor of Mcl-1 with sub-nanomolar affinity.

  • VU661013

    VU661013 (VU-661013) is a novel potent, selective MCL-1 inhibitor with Ki of 97 pM (human MCL-1) in TR-FRET assay.